I-Week-weekly Subinaneous Autoinjector
I-Rasuvo (methotrexate), i-auto-injection e-single-dose ene- dolotrexate , evunyiwe yi-US Food and Drug Administration (FDA) ngoJulayi 11, 2014. URasuvo, eyenziwe nguMedac, Pharma, Inc. sebenzisa okunye ukusetyenziswa komlomo we-methotrexate okanye ifom ye-vial-and-syringe ifayili.
Iimpawu zeRasuvo
I-Rasuvo ivunyiwe ukulawulwa kwezigulane ezinezifo ezinzima, ezichaphazelekayo ze- rheumatoid arthritis kunye ne- polyarticular yintsholongwane ye-idiopathic arthritis eyayineempendulo ezinganeleyo kunyango lokuqala okanye ingavumelani.
I-Rasuvo nayo iboniswe ukulawula iimpawu ezinxulumene nokukhawuleza, ukuphindaphinda, ukukhubaza i-psoriasis kubantu abadala abaphumelelanga ukufumana impendulo eyanelisayo kunye nezinye iindlela zokonyango. ( Qaphela: iRasuvo ayifanele isetyenziswe ekuphatheni izifo ze-neoplastic.)
Ulawulo lweRasuvo
I-Rasuvo ilawulwa kanye ngeveki nje nge-injection subcutaneous kuphela. I-Rasuvo ifumaneka kwiimitha ezili-10 zamandla ukusuka ku-7.5 mg ukuya kwi-30 mg (kwi-2.5 mg increments). I-autoinjector ikhutshwe ngesandla kwaye ifanele ijojowe esiswini nasemthangeni. Ezinye iifom ze-methotrexate kufuneka zisetyenziswe ukuba i-dosage engaphantsi kwe-7.5 mg okanye ngaphaya kwe-30 mg imiselwe-okanye ukuba utshintsho olungaphantsi kwe-2.5 mg luyimfuneko.
Umlinganiselo wokuqala we-methotrexate kwi-arthritis ye-rheumatoid i-7.5 mg kanye ngeveki ukuya kwilungu lomlomo okanye lincinci. I-psoriasis, i-dose yokuqala yesiqhelo i-10 mg mg kanye ngeveki nge-oral, intramuscular, subcutaneous, okanye intravenous administration.
Kwi-polyarticular juvenile idiopathic arthritis, i-dose yokuqala i-10mg / m2 kanye ngeveki nganye (m2 iyimitha engama-square yomhlaba).
Ngubani ongafanele asebenzise iRasuvo?
Izigulane ze-rheumatoid izifo ezikhulelwe akufanele zisebenzise uRasuvo. Kwakhona kufuneka kugwenywe ngabahlengikazi, kunye nezigulana ezijongene nazo: utywala okanye isifo sesibindi, i-immunodeficiency syndromes, okanye i-preexisting blood dyscrasias.
Izigulane ezine-hypersensitivity ezaziwayo ukuya kwi-methotrexate kufuneka ziphephe iRasuvo.
Izimpembelelo eziqhelekileyo
Kukho iziganeko eziqhelekileyo ezichaphazelekayo ezibandakanya iRasuvo kubandakanyeka, isicupunu, isisu, isisu okanye isilonda somlomo, i-nasopharyngitis, isifo sohudo, ukuhlolwa kwesibindi, ukuhlanza, intloko, i-bronchitis, i-thrombocytopenia (iiplatelet eziphantsi), i-alopecia, i-leukopenia (i-white white cell cell kubalwa), i-pancytopenia (inani eliphantsi kwezo zonke iintlobo zeeseli zegazi), utywala, kunye novelwano ekukhanyeni kwe-ultraviolet. Ukuba unempendulo engalunganga, unokuyibika kumenzi weziyobisi kwi-1-855-336-3322, kwi-FDA kwi-1-800-FDA-1088, okanye kwi-Medwatch kwi-http: //www.fda.gov/medwatch .
Ukusebenzisana kweziyobisi
Ugqirha wakho kufuneka abe nolwahlu lwawo onke amayeza kunye nezibonelelo ezithathayo ngoku. Qaphela ukuba ngokuthatha i-aspirin, i- NSAID , okanye amayeza e- corticosteroid kunye no-Rasuvo, amanqanaba e-serum methotrexate anokude (okt, unokuhlala egazini lakho ixesha elide) kwaye unokwandisa umngcipheko wezobisi.
Ukuthatha i-proton pump inhibitors (umz., I-Nexium okanye i-omeprazole) kunye neRasuvo inokunyusa amazinga e-serum methotrexate kunye nokwandisa umngcipheko wezobisi.
Izilumkiso kunye nokuqapha
I-Rasuvo iquka isilumkiso esisinikiweyo (isilumkiso esinzima kakhulu).
Iimpawu eziqingqiweyo zeNgqungquthela yeBhokisi:
- URasuvo kufuneka isetyenziswe kuphela oogqirha ngolwazi namava e-antimetabolite unyango. I-Rasuvo yi-inhibitor ye-antiog metabolic.
- Ngenxa yezinto ezinobungozi ezinobungozi, mhlawumbi ezibulalayo, iRasuvo kufuneka imiselwe kuphela labo abane-rheumatoid arthritis, i-psoriasis, okanye i-polyarticular yintsholongwane ye-idiopathic arthritis abangazange bayiphendule kwezinye iindlela.
- I-Methotrexate ibangelwa ukufa komntwana okanye ukungazalwa komntwana.
- I-Methotrexate yokupheliswa kwehla iyancipha kulabo abaneempilweni ezingasebenzi kakuhle, i-ascites, okanye i-effusion effusion.
- Ukunciphisa umongo we-Bone, i-anemia ye-anemia, kunye nokutywala kwesisu kunokungalindelekanga kwaye kungahle kubulawe xa i-methotrexate ithathwa nge-NSAID.
- Ukusetyenziswa ixesha elide le methotrexate kungabangela i-hepatotoxicity, fibrosis, kunye ne-cirrhosis. Iimvavanyo ze-biopsy zesibindi zingabonakaliswa.
- Izifo zamaphaphu ezibangelwa i-Methotrexate (umz., I-pneumonitis ekhulayo kunye engapheliyo) inokuthi ivele, nakwizinga eliphantsi.
- I-diarrhea kunye nesifo se-ulcerative stomatitis kufuna ukuba unyango kunye ne-methotrexate lugweme ukukhusela umnthamo we-intestinal okanye ukungena kwi-entitis.
- I-malignant lymphoma ingahlakulela nangona umthamo we-methotrexate ophantsi. Isiza kufuneka siyeke ukuba sibone ukuba i-lymphoma ihamba.
- I-Methotrexate inokubangela "i-tumor lysis syndrome" kwizigulane ezikhulayo ngokukhawuleza.
- Ukukhulula, ngamanye amaxesha ukubulala, ukuguquka kwesikhumba kunokwenzeka nge-methotrexate.
- Kungenzeka ukuba izifo ezichaphazelekayo ezichaphazelekayo zingenzeka nge-methotrexate.
- Ukuba i-methotrexate inikwe kunye kunye ne-radiotherapy, kunokukho ukwanda kwengozi ye-necrosis kunye ne- osteonecrosis .
Ngaphantsi
I-Rasuvo yindlela efanelekileyo yokwenza i-methotrexate. I-Rasuvo ithwala zonke iziphumo ezinobungozi kunye nezilumkiso zebhokisi ezinxulumene nezinye iifom of methotrexate.
Imithombo
Rasuvo. Ukwazisa ngokugcwele . Ebuyekeziwe 7/2014.
Imbali yokuVunywa kweRasuvo. drug.com.